A team of CSU scientists were awarded a base contract from the National Institute of Allergy and Infectious Diseases (NIAID), a part of the National Institutes of Health. The additional funding will support pre-clinical research and Phase I human clinical trials to test the safety and immune response of CSU’s SolaVAX™vaccine.